Pulmonary Hypertension Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

Systemic sclerosis-associated pulmonary hypertension and systemic sclerosis-associated interstitial lung disease exhibit similar but distinct gene expression profiles.

Pulmonary Hypertension Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.

Pulmonary Hypertension Patient Age Linked With Specific PAH Clinical Profile and Prognosis

Patient Age Linked With Specific PAH Clinical Profile and Prognosis

Patients with pulmonary hypertension age ≥65 years have worse long-term survival compared with younger patients.

Pulmonary Hypertension PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

The time course of pulmonary arterial hypertension was an independent risk factor for pulmonary artery aneurysms.

Pulmonary Hypertension Exercise Capacity in CTEPH Improved With Treprostinil

Exercise Capacity in CTEPH Improved With Treprostinil

Compared with the low dose, high-dose subcutaneous treprostinil increased 6-minute walk distances in patients with chronic thromboembolic pulmonary hypertension.

Pulmonary Hypertension Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.

Pulmonary Hypertension Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease Subtypes

Pulmonary Hypertension Screening Adaptations for Adult Congenital Heart Disease Subtypes

Because standardized approaches for echocardiographic screening are impractical for certain subgroups of people with congenital heart disease, experts offered screening adaptations for pulmonary hypertension.

Pulmonary Hypertension Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

Pulmonary Thromboendarterectomy Curative for CTEPH Linked to APS

Pulmonary thromboendarterectomy appears to be a curative resolution in patients with antiphospholipid syndrome related to chronic thromboembolic pulmonary hypertension.

Pulmonary Hypertension Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

Exercise Oxygen Desaturation, Pulmonary Function Predict Outcomes in SSc-PH

Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.

Pulmonary Hypertension Pulmonary Vascular Disease and Late Respiratory Disease Link in Preterm Infants

Pulmonary Vascular Disease and Late Respiratory Disease Link in Preterm Infants

Preterm infants who need mechanical ventilation at day 7 and early echocardiographic evidence of pulmonary vascular disease are strong risk factors for late respiratory disease.

Pulmonary Hypertension Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

Follow-Up Hemodynamics in Systemic Sclerosis-PAH Associated With 1-Year Outcomes

At follow-up, the 6-minute walk distance, cardiac index, stroke volume index, and other hemodynamic variables were independently associated with transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension.

CHEST 2018 RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

RV Hemodynamics Improved With Riociguat in Pulmonary Arterial Hypertension

Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.

CHEST 2018 High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

High Treprostinil Doses Delay PAH-Related and All-Cause Hospitalizations

Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.

CHEST 2018 Macitentan Tolerated in Portopulmonary Hypertension

Macitentan Tolerated in Portopulmonary Hypertension

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.

Pulmonary Hypertension Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

Pulmonary Artery Wedge Pressure and LVEDP Variance in Pulmonary Hypertension

In some patients at risk for pulmonary hypertension, left ventricular end diastolic pressure measurement with standard right heart catheterization should be used.

Pulmonary Hypertension Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Pulmonary Hypertension Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.

Pulmonary Hypertension Segmental Pulmonary Hypertension: Management of New Classification

Segmental Pulmonary Hypertension: Management of New Classification

Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.

Pulmonary Hypertension Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

Pulmonary Hypertension VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.

Pulmonary Hypertension Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Pulmonary Hypertension Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

Early Pulmonary Vascular Disease Onset Risk in Adults Born Preterm

Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.

Pulmonary Hypertension Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.

Pulmonary Hypertension PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

Although there were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.

Pulmonary Hypertension Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.

Pulmonary Hypertension Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.

Pulmonary Hypertension RV Trabecular Complexity Fractal Analysis: Measuring Remodeling in PH

RV Trabecular Complexity Fractal Analysis: Measuring Remodeling in PH

The fractal dimension of right ventricular trabecular complexity was a good reproducible marker of remodeling in pulmonary hypertension.

Pulmonary Hypertension RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.

Pulmonary Hypertension Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.

Pulmonary Hypertension PAH in Congenital Heart Disease: Challenges and Advances

PAH in Congenital Heart Disease: Challenges and Advances

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Pulmonary Hypertension Worsening Shortness of Breath in Patient With Hypertension, Afib

Worsening Shortness of Breath in Patient With Hypertension, Afib

A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.

Pulmonary Hypertension Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.

Pulmonary Hypertension Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation.

Restrictive Lung Disease Venoarterial ECMO Improves Survival to Transplant in Interstitial Lung Disease

Venoarterial ECMO Improves Survival to Transplant in Interstitial Lung Disease

In patients with end-stage interstitial lung disease, there was a higher rate of survival to transplantation with venoarterial extracorporeal membrane oxygenation.

Pulmonary Hypertension Oxygen Therapy Affects Health-Related QoL in Pulmonary Hypertension

Oxygen Therapy Affects Health-Related QoL in Pulmonary Hypertension

Strong relationships were observed between health-related quality-of-life scores and factors such as breathlessness, fatigue, depression, anxiety, and sleep in pulmonary hypertension.

Restrictive Lung Disease Double Lung Transplantation Improves Survival in Interstitial Pulmonary Fibrosis

Double Lung Transplantation Improves Survival in Interstitial Pulmonary Fibrosis

Double lung transplantation appears to offer superior survival outcomes to single lung transplantation in patients with interstitial pulmonary fibrosis who are younger than 70 years.

Pulmonary Hypertension Age-Obesity Interaction in Pulmonary Arterial Hypertension

Age-Obesity Interaction in Pulmonary Arterial Hypertension

The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.

Pulmonary Hypertension PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

Pulmonary Hypertension CTEPH Increases Risk for Sleep Disordered Breathing

CTEPH Increases Risk for Sleep Disordered Breathing

Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.

Pulmonary Hypertension Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Pulmonary Hypertension Clinical Trials in PAH: Interpreting Risk Reduction With Caution

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

Researchers raise issues regarding interpretation of clinical trial results in the field of pulmonary arterial hypertension.

Pulmonary Hypertension PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

Researchers modified the inhalation technique of iloprost in a patient with pulmonary arterial hypertension by attaching a nasal cannula to the inhalator's inlet port, shortening the administration duration.

Pulmonary Hypertension Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

Pulmonary Hypertension Arrhythmia Associated With Higher Mortality in Congenitial Heart Disease-Related PAH

Arrhythmia Associated With Higher Mortality in Congenitial Heart Disease-Related PAH

Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.

Pulmonary Hypertension Right Ventricular Stroke Work Effective Biomarker in Pediatric PAH

Right Ventricular Stroke Work Effective Biomarker in Pediatric PAH

Clinical worsening in pediatric pulmonary arterial hypertension may be predicted using right ventricular stroke work indexed by ejection fraction.

Pulmonary Hypertension Composite Echo Score Predicts PH in Interstitial Lung Disease

Composite Echo Score Predicts PH in Interstitial Lung Disease

The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.

COPD Potential COPD Pulmonary Vascular Phenotype Associated With Poor Outcomes

Potential COPD Pulmonary Vascular Phenotype Associated With Poor Outcomes

A definition of a pulmonary vascular phenotype of chronic obstructive pulmonary disease has been proposed.

Pulmonary Hypertension Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.

Pulmonary Hypertension Poor Subpleural Perfusion May Predict Balloon Pulmonary Angioplasty Failure

Poor Subpleural Perfusion May Predict Balloon Pulmonary Angioplasty Failure

Poor subpleural perfusion in patients with nonoperable chronic thromboembolic pulmonary hypertension may predict balloon pulmonary angioplasty failure.

Pulmonary Hypertension Metformin May Benefit Pulmonary Hypertension Associated With HFpEF, But Not PAH

Metformin May Benefit Pulmonary Hypertension Associated With HFpEF, But Not PAH

Although metformin prevented the development of PAH in hypoxia and monocrotalinerat models and reversed PAH in SU5416/hypoxia rats, it failed to reverse pulmonary pressures and vascular remodeling in mice with SU5416/hypoxia-induced PAH.

Pulmonary Hypertension PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus in pulmonary arterial hypertension should be considered separate diseases.

Pulmonary Hypertension Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.

Pulmonary Hypertension PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

The Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire has good psychometric properties and can be administered in clinical practice.

Pulmonary Hypertension Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.

Pulmonary Hypertension Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).

Pulmonary Hypertension Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Pulmonary Hypertension YEARS Criteria in Pulmonary Embolism Evaluation May Reduce Need for Imaging

YEARS Criteria in Pulmonary Embolism Evaluation May Reduce Need for Imaging

D-dimer test adjustment based on pretest probability results may be a safe option to reduce the need for imaging during evaluation for pulmonary embolism.

Pulmonary Hypertension Copeptin May Serve as Prognostic Biomarker for Pulmonary Embolism

Copeptin May Serve as Prognostic Biomarker for Pulmonary Embolism

Copeptin may be useful for identifying normotensive patients with pulmonary embolism who have a higher risk for an adverse outcome.

Pulmonary Hypertension Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.

Pulmonary Hypertension Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Pulmonary Hypertension Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Pulmonary Hypertension Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Pulmonary Hypertension Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

Pulmonary Hypertension PAAT May Detect Pulmonary Vascular Disease in Preterm Infants

PAAT May Detect Pulmonary Vascular Disease in Preterm Infants

Regardless of neonatal lung disease status, infants born before 29 weeks' gestation demonstrated abnormal pulmonary artery acceleration time at 1-year corrected age.

Pulmonary Hypertension Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

COPD Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Pulmonary Hypertension Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Pulmonary Hypertension Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Pulmonary Hypertension Outcomes Predicted by NT-proBNP

Pulmonary Hypertension Outcomes Predicted by NT-proBNP

N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.

Pulmonary Hypertension Pulmonary Hypertension Mortality Following Cardiac Catheterization

Pulmonary Hypertension Mortality Following Cardiac Catheterization

Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.

Pulmonary Hypertension Pulmonary Hypertension With HFpEF Mortality Predicted by Hemodynamic Markers

Pulmonary Hypertension With HFpEF Mortality Predicted by Hemodynamic Markers

The hemodynamic parameters predict mortality and cardiac hospitalization in patients with heart failure with preserved ejection fraction.

Pulmonary Hypertension Middle-Aged Woman With Progressive Exertional Dyspnea

Middle-Aged Woman With Progressive Exertional Dyspnea

A 57-year-old woman has been experiencing progressive exertional dyspnea during the past 6 months as well as a near syncopal episode while attempting to catch a taxi.

Trial Tracker

Hemodynamic markers of pulmonary hypertension in heart failure with preserved ejection fraction are associated with mortality

Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are predictors of mortality and cardiac hospitalizations in pulmonary hypertension associated with heart failure with preserved ejection fraction.

Pulmonary Hypertension A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

Several months after being diagnosed with pulmonary arterial hypertension, a 32-year-old pregnant woman presents with worsening dyspnea.

Pulmonary Hypertension PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions for US veterans are inconsistent with pulmonary hypertension guidelines.

Pulmonary Hypertension Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Patients with pulmonary arterial hypertension may be better identified through a claims-based algorithm that includes ICD-9-CM codes, specific pulmonary arterial hypertension medications, echocardiography, and right heart catheterization.

Pulmonary Hypertension Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Women with pulmonary arterial hypertension experienced better long-term prognosis than men with PAH.

Pulmonary Hypertension Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Enlargement of the right atrium is associated with an increased risk for supraventricular arrhythmias in PAH.

Pulmonary Hypertension Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose veins may increase the risk for pulmonary embolism and peripheral artery disease.

Pulmonary Hypertension Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Peak circulatory power offers greater value than peak oxygen uptake and ventilation in predicting cardiac events in patients with idiopathic PAH.

Pulmonary Hypertension Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in individuals with idiopathic PAH is associated with increased mortality risk.

Pulmonary Hypertension Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Observation in the emergency department followed by outpatient management with anticoagulation may be appropriate treatment for some patients with low-risk pulmonary embolism.

Pulmonary Hypertension Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

In patients at very low risk for pulmonary embolism, the pulmonary embolism rule-out criteria was noninferior to the conventional strategy of identifying thromboembolic events.

Trial Tracker

Pulmonary Embolism Rule-out Criteria non-inferior to usual care for patients at low-risk for pulmonary embolism

In this multicenter, randomized controlled study, the Pulmonary Embolism Rule-out Criteria (PERC) strategy resulted in significantly fewer uses of CT pulmonary angiography, reduced ED length of stay, and fewer hospital admissions.

Trial Tracker

Low prevalence of pulmonary embolism among patients with syncope

Based on this retrospective cohort study from multiple countries, the prevalence of pulmonary embolism in patients presenting to the emergency department with syncope was low.

Pulmonary Hypertension Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Patients with suspected PH should undergo two 6MWTs to improve the accuracy of exercise capacity measurements.

Pulmonary Hypertension Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.

Pulmonary Hypertension Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.

Pulmonary Hypertension Pulmonary Arterial Hypertension: Improving Survival Rates

Pulmonary Arterial Hypertension: Improving Survival Rates

Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.

Trial Tracker

Thyroid hormone supplementation may be a promising treatment for idiopathic pulmonary fibrosis [PreClinical]

An enzyme involved in thyroid hormone activation was found to be elevated in patients with pulmonary fibrosis.

Pulmonary Hypertension Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.

Pulmonary Hypertension Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.

Pulmonary Hypertension Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.

Pulmonary Hypertension New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.

Pulmonary Hypertension REVEAL Risk Score for Long-Term Outcomes in PAH

REVEAL Risk Score for Long-Term Outcomes in PAH

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

Pulmonary Hypertension PAH: Implantable Treprostinil Delivery System Is Promising

PAH: Implantable Treprostinil Delivery System Is Promising

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Hypertension Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.

Pulmonary Hypertension Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.

Pulmonary Hypertension Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.

Sign Up for Free e-newsletters